Traversa Therapeutics, Inc. Appoints Curt W. Bradshaw, Ph.D. as VP of Research & Development

SAN DIEGO--(BUSINESS WIRE)--Traversa Therapeutics, a preclinical-stage biopharmaceutical company developing novel RNA interference (RNAi) technologies, announced today the appointment of Curt W. Bradshaw, Ph.D., as the company’s Vice President of Research and Development. With extensive life science industry experience, Dr. Bradshaw provides Traversa with key leadership expertise to support the company’s ongoing efforts to advance its RNAi technologies into the clinics.

MORE ON THIS TOPIC